Development of omega-3 phospholipid-based solid dispersion of fenofibrate for the enhancement of oral bioavailability
Authors:
- 1 October 2015
- journal article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 78, 103-110
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea
- Ministry of Education (NRF-2013R1A1A2061289)
This publication has 37 references indexed in Scilit:
- Krill Oil for Cardiovascular Risk Prevention: Is it for Real?Hospital Pharmacy, 2014
- Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: Case studies with fenofibrateEuropean Journal of Pharmaceutics and Biopharmaceutics, 2014
- Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro–in silico–in vivo approachEuropean Journal of Pharmaceutics and Biopharmaceutics, 2013
- Drug precipitation–permeation interplay: Supersaturation in an absorptive environmentEuropean Journal of Pharmaceutics and Biopharmaceutics, 2012
- Phospholipids and Lipid-Based Formulations in Oral Drug DeliveryPharmaceutical Research, 2010
- Preparation of drug nanocrystals by controlled crystallization: Application of a 3-way nozzle to prevent premature crystallization for large scale productionEuropean Journal of Pharmaceutical Sciences, 2009
- A novel bottom–up process to produce drug nanocrystals: Controlled crystallization during freeze-dryingJournal of Controlled Release, 2008
- The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacyCurrent Atherosclerosis Reports, 2004
- Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectivesAtherosclerosis, 2003
- Some comments on the degree of crystallinity defined by the enthalpy of meltingPolymer, 1995